Publications 2018

Publications (original articles or review articles) published in 2019 from OUS - Metastasis - biology and therapy

13 publications found

Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Int J Nanomedicine, 14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Publications 2017

Publications (original articles or review articles) published in 2019 from OUS - Metastasis - biology and therapy

13 publications found

Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Int J Nanomedicine, 14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Publications 2016

Publications (original articles or review articles) published in 2019 from OUS - Metastasis - biology and therapy

13 publications found

Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Int J Nanomedicine, 14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Publications 2015

Publications (original articles or review articles) published in 2019 from OUS - Metastasis - biology and therapy

13 publications found

Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Int J Nanomedicine, 14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Publications 2014

Publications (original articles or review articles) published in 2019 from OUS - Metastasis - biology and therapy

13 publications found

Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Int J Nanomedicine, 14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Publications 2013

Publications (original articles or review articles) published in 2019 from OUS - Metastasis - biology and therapy

13 publications found

Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Int J Nanomedicine, 14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Publications 2012

Publications (original articles or review articles) published in 2019 from OUS - Metastasis - biology and therapy

13 publications found

Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Int J Nanomedicine, 14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Publications 2011

Publications (original articles or review articles) published in 2019 from OUS - Metastasis - biology and therapy

13 publications found

Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Int J Nanomedicine, 14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Annual summary Institute for Cancer Research

Publications (original articles or review articles) published in 2019 from OUS - Metastasis - biology and therapy

13 publications found

Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Int J Nanomedicine, 14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Publications

Publications (original articles or review articles) published in 2019 from OUS - Metastasis - biology and therapy

13 publications found

Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Sci Rep, 9 (1), 5670
DOI 10.1038/s41598-019-42153-6, PubMed 30952976

Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
DOI 10.1186/s13058-018-1092-x, PubMed 30670061

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Int J Nanomedicine, 14, 6269-6285
DOI 10.2147/IJN.S208938, PubMed 31496685

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006